Clinical Study

Fetuin-A Characteristics during and after Pregnancy: Result from a Case Control Pilot Study

Serdar Farhan,1 Ammon Handisurya,2 Jelena Todoric,2 Andrea Tura,3
Giovanni Pacini,3 Oswald Wagner,4 Katharina Klein,5 Rudolf Jarai,1 Kurt Huber,1
and Alexandra Kautzky-Willer2

1 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Montleartstrasse 37, 1160 Vienna, Austria
2 Gender Medicine Unit, Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
3 Metabolic Unit, Institute of Biomedical Engineering, National Research Council, Padova, Italy
4 Clinical Institute for Medical and Chemical Laboratory Diagnostic, General Hospital of Vienna, Vienna, Austria
5 Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

Correspondence should be addressed to Serdar Farhan, serdarfarhan@yahoo.de

Received 30 October 2011; Accepted 23 January 2012

Academic Editor: Graziano Di Cianni

Copyright © 2012 Serdar Farhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Fetuin-A has been associated with gestational diabetes mellitus (GDM). We investigated fetuin-A levels during and after pregnancy in women with GDM. Fetuin-A measurements were performed in 10 women with GDM and 10 age and body mass index (BMI) matched healthy pregnant women. All women underwent an oral glucose tolerance test (OGTT) in and 3 months after gestation. Results. Fasting fetuin-A correlated with BMI in women with former GDM ($r = 0.90, P < 0.0001$) but showed no association with parameters of glucose tolerance in women with GDM or post-GDM. GDM featured significantly lower insulin sensitivity and higher insulin and C-peptide secretion profiles compared to NGT during pregnancy ($P < 0.05$). Fasting and postprandial fetuin-A did not differ between groups, neither during nor after pregnancy. Conclusion. Fetuin-A is not influenced by glucose tolerance during or after pregnancy or acute glucose elevations following glucose ingestion in young women, but closely relates to BMI early postpartum.

1. Introduction

Fetuin-A is a potent systemic calcification inhibitor [1]. Beside this function fetuin-A has been shown to interact with insulin receptor tyrosine kinase, thereby inducing insulin resistance in rodents [2, 3]. In cross-sectional human studies, fetuin-A has been linked to insulin resistance and metabolic syndrome [4]. Furthermore fetuin-A has been linked to incident diabetes mellitus in the Health ABC study [5]. Stefan et al. were able to demonstrate a relation between fetuin-A and liver fat accumulation in insulin-resistant subjects [6]. In pregnant women fetuin-A levels were shown to increase with gestational age [7]. Furthermore women with gestational diabetes (GDM) display higher levels of fetuin-A compared to normal glucose tolerant counterparts [7]. However, GDM being regarded as pre-type 2 diabetes may comprise a very heterogeneous group of women of different ethnicity and with varying degree of obesity. Therefore, investigating fetuin-A behavior in women with GDM may provide a possibility to further elucidate the role of fetuin-A in early stages of diabetes mellitus. Therefore we aimed to investigate the role of acute glucose ingestion during a standardized oral glucose tolerance test (OGTT) on plasma fetuin-A levels in a homogeneous group of European young normal-weight to moderately overweight women with and without GDM during as well as after partum.
2. Methods

The study was performed as a case-control study. Women with GDM were recruited consecutively from the Department of Obstetrics and Gynecology of the Medical University of Vienna. Those who gave informed consent underwent a 2 h oral glucose tolerance test (OGTT). Data from 10 women with GDM and 10 women with NGT during pregnancy (28th week of gestation), matched for age and BMI in a 1:1 ratio, were analyzed. A second OGTT was performed 10–12 weeks after delivery. Women with previous ketoacidosis and/or beta-cell antibodies (GAD, ICA, IA2), severe chronic disease, kidney or liver disease, and those on chronic medication of drugs known to influence carbohydrate metabolism were excluded.

2.1. OGTT. GDM was diagnosed according to the criteria of the 4th International Workshop Conference on GDM [8]. After an overnight fast for at least 12 h, blood samples for the measurement of glucose, insulin, and C-peptide were taken at baseline as well as at 30, 60, 90, and 120 min after ingestion of 75 g glucose. Fetuin-A levels were measured at fasting as well as 30, 60, and 120 minutes after glucose load.

2.2. Plasma Metabolites. Plasma levels of fetuin-A were measured by an enzyme-linked radioimmunoassay (ELISA) (Biovendor laboratory medicine, Modreci, Czech republic). Intra-assay coefficients of variation were 3.5% and interassay coefficient of variation 5.4%. Glucose, insulin, C-peptide, glutamate oxalacetat transaminase (GOT), glutamat-pyruvat-transaminase (GPT), bilirubin, cholinesterase (CHE), cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglyceride (TG), and HbA1c were measured using standard kits available in our central laboratory.

2.3. Data Analysis. The kinetics of glucose, insulin, and C-peptide during OGTT were analyzed by quantitative methods to obtain metabolic parameters, such as insulin sensitivity through oral glucose insulin sensitivity index (OGIS), which describes glucose clearance per unit change of insulin concentration [9]. Total insulin secretion (TIS) from C-peptide, its suprabasal component (dynamic TIS), and hepatic insulin extraction (HIE) were obtained with a mathematical model of insulin/C-peptide interactions [10, 11]. β-Cell function was described as the ability of the β-cell to adapt insulin secretion to the prevailing insulin resistance and was quantified by the products: OGIS,dynamic AUC insulin (termed disposition index) and OGIS,dynamic TIS (termed adaptation index), where AUC is the area under the insulin concentration curve during the whole test.

2.4. Statistical Analysis. Comparisons of quantitative variables among groups were performed using Student's t-test. Associations between continuous variables are described by the Spearman correlation coefficient. Levels of statistical significance were set at $P < 0.05$.

3. Results

Women with and without GDM were comparable in terms of their medical history. There were also no differences in baseline as well as 3 months postpartum laboratory parameters of lipoproteins and liver enzymes (Table 1). During gestation women with GDM displayed significant higher fasting insulin, C-peptide, and AUC of both parameters during OGTT. OGIS was significantly lower in women with GDM compared to those with NGT (Table 1) and Figure 1(a).

Three months after delivery, 3 women from the GDM group had a pathologic glucose tolerance status and the remaining 7 returned to normal glucose values. Insulin and C-peptide secretion profiles were still higher in women from the former GDM compared to NGT group but without reaching statistical significance (Table 1). Also OGIS were still lower in the former GDM group compared to women with NGT without statistical significance (Table 1) and Figure 1(b).

Fasting and postprandial fetuin-A plasma levels did not differ between women with GDM and NGT during as well as 3 months after pregnancy (Table 1). During pregnancy there were no correlations between fetuin-A plasma levels and parameters of insulin resistance and secretion. Three months after gestation there was significant correlation between fasting fetuin-A and BMI ($r = 0.90, P < 0.0001$) in women with former GDM (Figure 2). There were no correlations between fetuin-A plasma concentrations and GOT, GPT, or bilirubin.

4. Discussion

In the present study we found that fetuin-A plasma levels did not differ between women with and without GDM even when measured during as well as after pregnancy. Additionally, we found that fetuin-A was not affected by acute glucose ingestion both during as well as after gestation. Interestingly we found that fetuin-A did not correlate with parameters of obesity and insulin resistance during pregnancy. However three months after gestation there was a strong correlation between fasting fetuin-A and BMI in those from the former GDM group. One study investigated the relation between fetuin-A levels and parameters of insulin resistance during normal pregnancy and in women with GDM [7]. In that study fetuin-A levels increased during the course of uncomplicated gestation [7]. Additionally women with GDM had significantly higher fetuin-A levels compared to healthy pregnant women [7]. Furthermore they found a significant correlation between fetuin-A levels and parameters of insulin resistance such as fasting C-peptide and C-peptide to glucose ratio [7]. However the differences between those results and our findings could be explained by study design and methods. GDM women in the study of Kabaly et al. were more obese than subjects in our investigation. Furthermore we used more sophisticated methods to measure insulin resistance. Under experimental conditions high glucose levels were able to activate fetuin-A gene promoter [12]. This activation was dose dependent and occurred after at least 3
Figure 1: (a) Boxplot of OGIS level (mL min$^{-1}$ m$^{-2}$) in women with and without gestational diabetes mellitus during pregnancy ($P = 0.001$). (b) Boxplot of OGIS level (mL min$^{-1}$ m$^{-2}$) in women with and without gestational diabetes mellitus 3 months after delivery ($P = 0.06$).

Table 1: Patient’s characteristics and laboratory parameters.

| Variable                          | Third trimester of gestation | P-Value | Three months postpartum | P Value |
|-----------------------------------|------------------------------|---------|--------------------------|---------|
|                                   | NGT ($n = 10$) | GDM ($n = 10$) | | NGT ($n = 10$) | GDM ($n = 10$) | |
| BMI (Kg/m$^2$)                    | 27.3 ± 1.3 | 28.9 ± 1.31 | 0.4          | 26.5 ± 1.58 | 27.9 ± 1.30 | 0.5         |
| Age (years)                       | 30.4 ± 1.7 | 32 ± 2.3   | 0.5          | —            | —            | —           |
| Parity                            | 1.1 ± 0.4  | 2 ± 1      | 0.4          | —            | —            | —           |
| Systolic blood pressure (mmHg)    | 116.5 ± 4.2| 110 ± 4.1  | 0.2          | 117.6 ± 2.9 | 106.4 ± 4.4 | 0.05        |
| Diastolic blood pressure (mmHg)   | 71.5 ± 2.5 | 67.7 ± 2   | 0.2          | 73.1 ± 2.4  | 65 ± 2.6    | 0.04        |
| Total cholesterol (mg/dL)         | 277.1 ± 16.4| 227.2 ± 11.6| 0.02        | 204.5 ± 15.2| 203 ± 10.2 | 0.9         |
| LDL cholesterol (mg/dL)           | 159 ± 14.8 | 115 ± 9.1  | 0.02        | 129.5 ± 13  | 118.4 ± 6.8 | 0.4         |
| HDL cholesterol (mg/dL)           | 75.6 ± 21.3| 69.9 ± 3.7 | 0.4          | 64.7 ± 6   | 61.6 ± 4.5 | 0.6         |
| Triglycerides (mg/dL)             | 197.1 ± 20.2| 207 ± 24.9| 0.7          | 81 ± 7.5   | 116.3 ± 18.7| 0.09        |
| HbA1c (%)                         | 4.9 ± 0.11 | 4.9 ± 0.14 | 0.9          | 5.2 ± 0.1  | 5.3 ± 0.08 | 0.5         |
| Cholinesterase ()                 | 5.31 ± 0.71| 5.23 ± 1.39| 0.6          | 7.07 ± 0.7 | 7.76 ± 1.48 | 0.1         |
| Bilirubin ()                      | 0.33 ± 0.13 | 0.37 ± 0.14 | 0.5            | 0.7 ± 0.42  | 0.48 ± 0.16  | 0.1         |
| GOT (U/L)                         | 21.6 ± 5.1 | 20.1 ± 3.9 | 0.8          | 26.3 ± 7.5 | 26.3 ± 8.9 | 0.2         |
| GPT (U/L)                         | 15.8 ± 6.1 | 17.1 ± 7.4 | 0.4          | 27 ± 13.7  | 40.1 ± 23.3 | 0.9         |
| hs-CRP (mg/dL)                    | 0.43 ± 0.05 | 2.15 ± 1.75 | 0.3          | 0.29 ± 0.07  | 0.21 ± 0.07  | 0.5         |
| Fasting glucose (mg/dL)           | 80.3 ± 2.3 | 88.1 ± 2.6 | 0.039        | 82.4 ± 2.9  | 92.4 ± 3.6 | 0.04        |
| 1-hour postload glucose (mg/dL)   | 135.6 ± 7.2| 186.1 ± 11.5| 0.002        | 105.3 ± 8.6 | 114.1 ± 13.4| 0.6         |
| Fasting insulin secretion (pmol/L)| 12.2 ± 1.6 | 16.0 ± 1.8 | 0.1          | 7.8 ± 1.4  | 11.3 ± 2.3 | 0.2         |
| OGIS                              | 434.05 ± 12| 341.51 ± 19.35| 0.001      | 476.79 ± 30.23 | 408.19 ± 18.72 | 0.06       |
| Disposition index (nmol/m²³)      | 3.87 ± 0.44 | 5.15 ± 0.50 | 0.07        | 2.49 ± 0.43  | 3.57 ± 0.31  | 0.059       |
| AUC-glucose (mmol/L/min.)         | 14.21 ± 0.54| 19.28 ± 0.73| 0.0001    | 14.17 ± 0.89 | 17.26 ± 1.26 | 0.1         |
| AUC-insulin (nmol/L/min.)         | 8.93 ± 0.98 | 15.7 ± 2.01 | 0.007   | 5.41 ± 1.08  | 9.11 ± 1.15  | 0.46        |
| AUC-C-peptide (nmol/L/min.)       | 1016.7 ± 44.9| 1441.3 ± 137.9| 0.009    | 777.5 ± 98.9 | 1131.4 ± 156.3| 0.1         |
| Fasting fetuin-A (ng/mL)          | 497.5 ± 64.3| 580 ± 46.4 | 0.8          | 560.38 ± 69.3 | 571.4 ± 80.4 | 0.8         |
| 30-min. after load fetuin-A (ng/mL)| 453.9 ± 29.8| 549.3 ± 50 | 0.5          | 569.4 ± 86.1 | 571.3 ± 87.2 | 0.5         |
| 60-min. after load fetuin-A (ng/mL)| 581 ± 43.2| 513 ± 42.1 | 0.7          | 577.5 ± 114.1 | 542.7 ± 43.8 | 0.7         |
| 120-min. after load fetuin-A (ng/mL)| 524.5 ± 39.9| 539.6 ± 33 | 0.1          | 414.8 ± 48.6 | 552 ± 47.6  | 0.1         |
hours of incubation [12]. In our study during OGTT fetuin-A plasma levels remained unchanged. We could not exclude a late elevation of fetuin-A after OGTT. Further studies with longer fetuin-A collection time points during OGTT or intravenous glucose tolerance test are needed to further investigate the influence of glucose per se on fetuin-A plasma concentrations.

However, the fact that even chronic hyperglycemia linked to GDM did not alter fetuin-A levels argues against a prominent effect of glucose fluctuations/elevation on fetuin-A release. Fetuin-A has been linked to obesity in a study performed in patients with morbid obesity [13]. In that study, fetuin-A levels decreased after weight loss due to gastric bypass surgery [13]. Another study investigated the relation between fetuin-A with parameters of insulin resistance and fatty liver [14]. In that study obese children with and without nonalcoholic fatty liver (NAFL) were compared. The authors found a relation between fetuin-A and NAFL as well as a reduction in fetuin-A after weight loss [14]. In our study we did not investigate the presence of NAFL by ultrasound as recommended. Despite this there were no differences in hepatic transaminases as well as cholinesterase between women with and without GDM neither in nor after pregnancy. Additionally we found no correlation of fetuin-A with those liver enzymes (data not presented). Women in our study were only of moderate obesity as compared to children which were besides having GDM healthy. Also the mean BMI of our GDM patients was lower than that of the subjects investigated by Kalabay et al. [7]. Third we did not investigate the presence of NAFL by ultrasound examination.

5. Conclusion

Our preliminary study suggests that fetuin-A does not relate to parameters of insulin sensitivity or metabolic control and does not seem to play a role in the pathogenesis of GDM. Furthermore acute glucose changes during an OGTT do not affect fetuin-A plasma concentrations both during and after pregnancy. However preexisting overweight, which may be masked by pregnancy, related changes in body weight or weight retention after pregnancy may have a strong impact on fetuin-A release.

References

[1] C. Schäfer, A. Heiss, A. Schwarz et al., “The serum protein α2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 357–366, 2003.
[2] P. Auburger, L. Falquerho, J. O. Contreres et al., “Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity,” Cell, vol. 58, no. 4, pp. 631–640, 1989.
[3] S. T. Mathews, N. Chellam, P. R. Srinivas et al., “α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor,” Molecular and Cellular Endocrinology, vol. 164, no. 1-2, pp. 87–98, 2000.
[4] J. H. Ix, M. G. Shlipak, V. M. Brandenburg, S. Ali, M. Ketteler, and M. A. Whooley, “Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study,” Circulation, vol. 113, no. 14, pp. 1760–1767, 2006.
[5] J. H. Ix, C. L. Wassel, A. M. Kanaya et al., “Fetuin-A and incident diabetes mellitus in older persons,” JAMA—Journal of the American Medical Association, vol. 300, no. 2, pp. 182–188, 2008.
[6] N. Stefan, A. M. Hennige, H. Staiger et al., “α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans,” Diabetes Care, vol. 29, no. 4, pp. 853–857, 2006.
[7] L. Kalabay, K. Cseh, A. Pajor et al., “Correlation of maternal serum fetuin/α2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes,” European Journal of Endocrinology, vol. 147, no. 2, pp. 243–248, 2002.
[8] American Diabetes Association, “Clinical practice recommendations,” Diabetes Care, vol. 25, supplement 1, pp. S1–S14, 2002.
[9] A. Mari, G. Pacini, E. Murphy, B. Ludvik, and J. J. Nolan, “A model-based method for assessing insulin sensitivity from the oral glucose tolerance test,” Diabetes Care, vol. 24, no. 3, pp. 539–548, 2001.
[10] A. Kautzy-Willer, A. Tura, C. Winzer et al., “Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in...
type 2 diabetic subjects under metformin and thiazolidinedione,” *Diabetes, Obesity and Metabolism*, vol. 8, no. 5, pp. 561–567, 2006.

[11] A. Tura, B. Ludvik, J. J. Nolan, G. Pacini, and K. Thomaseth, “Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT,” *American Journal of Physiology*, vol. 281, no. 5, pp. E966–E974, 2001.

[12] H. Takata, Y. Ikeda, T. Suehiro et al., “High glucose induces transactivation of the α₂-HS glycoprotein gene through the ERK1/2 signaling pathway,” *Journal of Atherosclerosis and Thrombosis*, vol. 16, no. 4, pp. 448–456, 2009.

[13] J. M. Brix, H. Stingl, F. Höllerl, G. H. Schernthaner, H. P. Kopp, and G. Schernthaner, “Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss,” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 11, pp. 4877–4881, 2010.

[14] T. Reinehr and C. L. Roth, “Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss,” *Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 11, pp. 4479–4485, 2008.